Jefferies Financial Group Inc. Takes $980,000 Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Jefferies Financial Group Inc. acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 80,899 shares of the company's stock, valued at approximately $980,000.

Other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. raised its holdings in shares of Elanco Animal Health by 66.7% in the 4th quarter. Blue Trust Inc. now owns 6,615 shares of the company's stock valued at $80,000 after acquiring an additional 2,647 shares in the last quarter. KBC Group NV lifted its holdings in Elanco Animal Health by 264.9% in the 4th quarter. KBC Group NV now owns 323,502 shares of the company's stock worth $3,918,000 after buying an additional 234,840 shares during the period. Institute for Wealth Management LLC. lifted its holdings in Elanco Animal Health by 11.5% in the 4th quarter. Institute for Wealth Management LLC. now owns 35,516 shares of the company's stock worth $430,000 after buying an additional 3,656 shares during the period. Spire Wealth Management lifted its stake in shares of Elanco Animal Health by 107.4% in the 4th quarter. Spire Wealth Management now owns 7,776 shares of the company's stock valued at $94,000 after purchasing an additional 4,026 shares during the period. Finally, Jennison Associates LLC lifted its stake in shares of Elanco Animal Health by 1.4% in the 4th quarter. Jennison Associates LLC now owns 1,095,710 shares of the company's stock valued at $13,269,000 after purchasing an additional 15,246 shares during the period. Hedge funds and other institutional investors own 97.48% of the company's stock.

Insider Buying and Selling

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company's stock in a transaction dated Tuesday, March 11th. The stock was purchased at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares in the company, valued at approximately $1,136,881.80. The trade was a 9.86% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.89% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Barclays lowered their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Morgan Stanley reduced their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Piper Sandler reduced their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. UBS Group reduced their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Finally, Stifel Nicolaus lifted their target price on Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Monday, May 19th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Elanco Animal Health has a consensus rating of "Hold" and an average target price of $15.17.

Elanco Animal Health Stock Performance

Shares of ELAN traded down $0.06 during trading hours on Friday, hitting $13.46. The stock had a trading volume of 7,178,699 shares, compared to its average volume of 5,120,755. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.80. The firm has a market capitalization of $6.68 billion, a PE ratio of 33.65, a PEG ratio of 2.50 and a beta of 1.49. The stock has a fifty day moving average price of $10.60 and a 200 day moving average price of $11.43.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the company posted $0.34 earnings per share. Elanco Animal Health's revenue was down 1.0% compared to the same quarter last year. Analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.